Activating Mutations in Pik3ca Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes.
Myeong-Kyun ShinSusan PayneAndrea BilgerKristina A MatkowskyjEvie CarchmanDominique S MeyerMohamed Bentires-AljDustin A DemingPaul F LambertPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
These data demonstrate that activating mutations in Pik3ca drive anal carcinogenesis together with HPV16 oncogenes, and that the PI3K/mTOR pathway is a relevant target for therapeutic intervention.